Trial Profile
A phase III, multi-center, randomized, double blind, active and placebo control, single dose trial to demonstrate the efficacy and safety of DWP-450 in adult subjects for treatment of moderate-to-severe glabellar lines
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jan 2023
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Glabellar lines
- Focus Registrational; Therapeutic Use
- Acronyms EV003
- Sponsors Evolus
- 23 Jan 2023 According to an Evolus media release, based on the safety and efficacy of Nuceiva from global TRANSPARENCY clinical program, which included two Phase III U.S. trials, the largest head-to-head aesthetic pivotal study versus BOTOX (onabotulinumtoxinA) to date, and two long-term safety studies, the Australian Therapeutic Goods Administration (TGA) has provided regulatory approval for Nuceiva for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients.
- 02 Jun 2022 Results of a new post hoc analysis of three single-dose, Phase III glabellar line clinical studies comparing millennial patients to non-millennials presented in an Evolus Media Release.
- 02 Jun 2022 According to an Evolus media release, data from a new post hoc analysis of three single-dose, Phase III glabellar line clinical studies comparing millennial patients to non-millennials, published in Dermatologic Surgery.